10 results about "Perillyl alcohol" patented technology

The present disclosure refers to therapeutic combinations and pharmaceutical compositions comprising glycolysis inhibitors / modulators and prenyltransferase inhibitors for treating brain tumors. In particular, the disclosure describes therapeutic combinations and pharmaceutical compositions of dichloroacetate (DCA) and perillyl alcohol (POH) useful for treating brain cancers such as glioblastoma multiforme (GBM). Additionally, the disclosure provides methods for treating GBM and other forms of brain cancer using the same.

This invention belongs to the field of biosynthesis, specifically relating to a variant of lysine pyrophosphate diol synthase and the constructed engineered yeast strain for perillaldehyde synthesis. To address the generally low yield of perillaldehyde biosynthesis in existing technologies, this invention mutates and optimizes the lysine pyrophosphate diol synthase to obtain an SsLPPs mutant containing the G379M mutation, which is then used for perillaldehyde synthesis. Simultaneously, to address the genetic instability issues associated with free plasmid expression in some Saccharomyces cerevisiae strains, this invention constructs a perillaldehyde synthesis pathway within the yeast genome. Furthermore, by enhancing the acetyl-CoA synthesis pathway, the MVA pathway, and the perillaldehyde synthesis pathway, and by knocking out some transcriptional repressors, the substrate strain synthesizing perillaldehyde is modified, resulting in a significantly increased yield compared to existing technologies.

The invention discloses a perillyl alcohol derivative as well as a preparation method and application thereof. The structural formula of the compound is as shown in formula I in the specification. The preparation method comprises the following steps: (1) reacting perillyl alcohol with p-chloromethyl benzoyl chloride to obtain an esterification reaction intermediate; and (2) carrying out nucleophilic substitution reaction on the esterification reaction intermediate and different substituted piperazines to obtain the target compound I. The compound disclosed by the invention has good activity on gastric cancer cells MKN45 and SGC-7901.

The application belongs to the technical field of animal disease prevention and control, and discloses application of a traditional Chinese medicine monomer, i.e., a perillyl alcohol, in preparation of a medicine for preventing or treating a pseudorabies of pigs. The application verifies the role of the perillyl alcohol in inhibiting a pig pseudorabies virus infection process and explores the application value of the perillyl alcohol in resisting the pig pseudorabies virus, and provides a theoretical basis and practical guidance for prevention and control of the PRV. In addition, the perillyl alcohol is a natural source medicine, has the advantages of safety, few side effects, low metabolic residues and no pollution, and has good popularization and application value.

The present disclosure refers to therapeutic combinations and pharmaceutical compositions comprising glycolysis inhibitors / modulators and prenyltransferase inhibitors for treating brain tumors. In particular, the disclosure describes therapeutic combinations and pharmaceutical compositions of dichloroacetate (DCA) and perillyl alcohol (POH) useful for treating brain cancers such as glioblastoma multiforme (GBM). Additionally, the disclosure provides methods for treating GBM and other forms of brain cancer using the same.

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

The invention discloses a perillaldehyde derivative as well as a preparation method and application thereof. The structural formula of the perillaldehyde derivative is shown in the specification. The compound disclosed by the invention is simple in structure and few in synthesis steps; the compound has an obvious inhibition effect on physalospora piricola, valsa mali, phytophthora capsici, rhizoctonia solani and gaeumannomyces graminis, and can be used as a bactericide for preventing and treating plant diseases.

This invention belongs to the field of biosynthesis, specifically relating to a variant of lysine pyrophosphate diol ester synthase and engineered bacteria for producing perillaldehyde. To address the generally low yield of perillaldehyde biosynthesis in existing technologies, this invention mutates and optimizes lysine pyrophosphate diol ester synthase, obtaining an SsLPPs mutant containing the D374L mutation, and uses this mutant for perillaldehyde synthesis. Simultaneously, to address the genetic instability issues associated with free plasmid expression in some Saccharomyces cerevisiae strains, this invention constructs a perillaldehyde synthesis pathway in the yeast genome. Furthermore, it modifies the substrate bacteria synthesizing perillaldehyde by enhancing the acetyl-CoA synthesis pathway, the MVA pathway, and the perillaldehyde synthesis pathway, and by knocking out some transcriptional repressors, resulting in a significant increase in yield compared to existing technologies.

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

The present application relates to a kind of biosynthesis methods of sclareolide, comprising the following steps: 1) in the fermentation process, every interval one sampling period t1, the content of sclareol in fermentation liquor is sampled and detected, and according to the content of sclareol in fermentation liquor detection value, the feeding speed of sclareol is adjusted;2) the volatilization amount of sclareol in fermentation tail gas is continuously detected, every interval one metering period t2, the volatilization total amount of sclareol is counted once, and the total amount of sclareol feeding in metering period is counted, the ratio of the volatilization total amount of sclareol and the total amount of sclareol feeding is calculated;3) when the ratio is less than threshold value, increase the feeding speed of sclareol.The present application judges the consumption variation of sclareol by continuously monitoring the ratio of the volatilization amount of sclareol in fermentation tail gas and the feeding amount of sclareol, can improve the timeliness of the concentration control of sclareol in fermentation liquor.The conversion rate and yield of biosynthesis sclareolide can be further improved by using the method.